TABLE 4.
In vitro drug combination studies with GS-9770
| Drug combined with GS-9770a | TAF | FTC | RPV | BIC | LEN | GS-9770 |
|---|---|---|---|---|---|---|
| Synergy volume [µM2.%]b | 166 ± 51 | 139 ± 24 | 184 ± 65 | 156 ± 49 | 201 ± 111 | 23 ± 14 |
| Antagonism volume [µM2.%]b | −4 ± 7 | −8 ± 11 | 0 ± 0 | −11 ± 13 | −0.6 ± 1.7 | −3 ± 3 |
| Combination effect | Highly synergistic | Highly synergistic | Highly synergistic | Highly synergistic | Highly synergistic | Additive |
a
TAF, tenofovir alafenamide (NRTI); FTC, emtricitabine (NRTI); RPV, rilpivirine (NNRTI); BIC, bictegravir (INSTI); EVG, elvitegravir (INSTI); LEN, lenacapavir (capsid inhibitor).
b
Combination volumes calculated at 99% confidence interval. Data are mean (± s.d.) values from at least three independent experiments (n = 3 biological replicates each).